Advertisement

Topics

Glycine vs Placebo for the Schizophrenia Prodrome

2014-08-27 03:46:09 | BioPortfolio

Summary

Glycine is a natural amino acid neurotransmitter that acts as a co-agonist at NMDA receptors in brain. We hypothesize that symptoms of the schizophrenia prodrome will improve with glycine to a greater degree than with placebo.

Study Design

Allocation: Randomized, Control: Placebo Control, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Conditions

Schizophrenia Prodrome

Intervention

Glycine, Placebo

Location

PRIME Clinic
New Haven
Connecticut
United States
06519

Status

Completed

Source

Yale University

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:46:09-0400

Clinical Trials [1015 Associated Clinical Trials listed on BioPortfolio]

Glycine Treatment of Prodromal Symptoms

This is an open label trial of the NMDA agonist glycine used alone for symptoms that appear to be prodromal for schizophrenia in adolescents and young adults.

Adjunctive Treatment for Decreasing Symptoms of Schizophrenia

This study will determine the effectiveness of treatment with glycine or d-cycloserine in addition to a normal antipsychotic regimen in improving negative symptoms and cognitive impairment...

Ethyl-EPA Treatment of Prodromal Patients

This is an open-label trial of an omega-3 fatty acid for symptoms of the schizophrenia prodrome.

A Study of the Effects of Sarcosine on Symptoms and Brain Glycine Levels in People With Schizophrenia

The purpose of this study is to evaluate the effect of a dietary supplement on the concentration of a small protein called glycine that is found in the brain in people with schizophrenia. ...

Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepines in First-Episode Schizophrenia

Prodrome based early intervention with an antipsychotic drug vs. benzodiazepine was applied in patients with first episode schizophrenia after one year neuroleptic maintenance treatment. T...

PubMed Articles [1994 Associated PubMed Articles listed on BioPortfolio]

Mutations of the Glycine Cleavage System Genes Possibly Affect the Negative Symptoms of Schizophrenia through Metabolomic Profile Changes.

Hypofunction of N-methyl-D-aspartate receptors (NMDARs) may contribute to the pathophysiology of schizophrenia (SCZ). Recently, the glycine cleavage system (GCS) was shown to affect NMDAR function in ...

Statin add-on therapy in the antipsychotic treatment of schizophrenia: A meta-analysis.

A comprehensive meta-analysis of statin add-on therapy in the antipsychotic treatment of schizophrenia was conducted. Data from previous studies, prior to 8/21/2017, was obtained from Scopus, PubMed, ...

Predictors of Placebo Response in Pharmacological Clinical Trials of Negative Symptoms in Schizophrenia: A Meta-regression Analysis.

We conducted a meta-regression analysis of all double-blind, randomized, placebo-controlled clinical trials (DBRCTs) reporting effects of drug and placebo on negative symptoms in people with stable sc...

Nigral Stress-Induced Dopamine Release in Clinical High Risk and Antipsychotic-Naïve Schizophrenia.

Striatal dopamine (DA) synthesis capacity and release are elevated in schizophrenia (SCZ) and its putative prodrome, the clinical high risk (CHR) state. Striatal DA function results from the activity ...

L-carnosine as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: A double-blind, randomized placebo-controlled trial.

Since l-carnosine has shown effectiveness in improvement of cognition in patients with schizophrenia, this 8-week, randomized, double-blind, placebo-controlled pilot study was conducted. Sixty-three p...

Medical and Biotech [MESH] Definitions

A PYRIDOXAL PHOSPHATE dependent enzyme that catalyzes the decarboxylation of GLYCINE with the transfer of an aminomethyl group to the LIPOIC ACID moiety of the GLYCINE DECARBOXYLASE COMPLEX H-PROTEIN. Defects in P-protein are the cause of non-ketotic hyperglycinemia. It is one of four subunits of the glycine decarboxylase complex.

A family of sodium chloride-dependent neurotransmitter symporters that transport the amino acid GLYCINE. They differ from GLYCINE RECEPTORS, which signal cellular responses to GLYCINE. They are located primarily on the PLASMA MEMBRANE of NEURONS; GLIAL CELLS; EPITHELIAL CELLS; and RED BLOOD CELLS where they remove inhibitory neurotransmitter glycine from the EXTRACELLULAR SPACE.

Cell surface receptors that bind glycine with high affinity and trigger intracellular changes which influence the behavior of cells. Glycine receptors in the central nervous system have an intrinsic chloride channel and are usually inhibitory.

An oxidoreductase that catalyzes the oxidative DEAMINATION of GLYCINE to glyoxylate and AMMONIA in the presence of NAD. In BACTERIA lacking transaminating pathways the enzyme can act in the reverse direction to synthesize glycine from glyoxylate and ammonia and NADH.

A chronic form of schizophrenia characterized primarily by the presence of persecutory or grandiose delusions, often associated with hallucination.

More From BioPortfolio on "Glycine vs Placebo for the Schizophrenia Prodrome"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Alzheimer's Disease
Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase  'plaques' and 'tangles' (mis-folded proteins) form in the brain. People with Al...

Psychiatry
Psychiatry is the study of mental disorders and their diagnosis, management and prevention.  Conditions include schizophrenia, severe depression and panic disorders among others. There are pharmaceutical treatments as well as other therapies to help...


Searches Linking to this Trial